Artivion (NYSE: AORT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Artivion reported 59 open-market sales of 510,999 shares ($19.5m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 10 September 2026 | Green Andrew M | SVP, Regulatory and Quality | Open-market sale | −11,480 | $24.97 | 40,160 | Form 4 |
| 3 September 2026 | Green Andrew M | SVP, Regulatory and Quality | Open-market sale | −1,493 | $26.02 | 51,640 | Form 4 |
| 2 September 2026 | Green Andrew M | SVP, Regulatory and Quality | Open-market sale | −6,510 | $27.27 | 53,133 | Form 4 |
| 19 August 2026 | Mackin James P | President & CEO | Open-market sale | −70,000 | $28.96 | 877,275 | Form 4 |
| 14 August 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | Open-market sale | −715 | $28.55 | 210,112 | Form 4 |
| 14 August 2026 | Green Andrew M | SVP, Regulatory and Quality | Open-market sale | −616 | $28.55 | 59,643 | Form 4 |
| 12 August 2026 | Holloway Jean F | SVP, General Counsel | Open-market sale | −977 | $28.49 | 184,118 | Form 4 |
| 11 June 2026 | Green Andrew M | SVP, Regulatory and Quality | Option exercise, 10b5-1 plan | +14,001 | $18.44 | 74,260 | Form 4 |
| 11 June 2026 | Green Andrew M | SVP, Regulatory and Quality | Open-market sale, 10b5-1 plan | −14,001 | $20.71 | 60,259 | Form 4 |
| 11 June 2026 | Green Andrew M | SVP, Regulatory and Quality | Option exercise, 10b5-1 plan | +30,000 | $11.03 | 90,259 | Form 4 |
| 11 June 2026 | Green Andrew M | SVP, Regulatory and Quality | Open-market sale, 10b5-1 plan | −30,000 | $20.69 | 60,259 | Form 4 |
| 2 June 2026 | Semedo Anthony B. | Director | Other | −6,325 | — | 40,635 | Form 4 |
| 2 June 2026 | Semedo Anthony B. | Director | Other | +6,325 | — | 6,325 | Form 4 |
| 18 May 2026 | Ackerman Thomas F | Director | Grant or award | +7,576 | — | 157,472 | Form 4 |
| 18 May 2026 | Bevevino Daniel J | Director | Grant or award | +7,576 | — | 157,637 | Form 4 |
| 18 May 2026 | Bullock James | Director | Grant or award | +7,576 | — | 76,223 | Form 4 |
| 18 May 2026 | Burbank Jeffrey H | Director | Grant or award | +7,576 | — | 61,372 | Form 4 |
| 18 May 2026 | Hoff Elizabeth A | Director | Grant or award | +7,576 | — | 34,765 | Form 4 |
| 18 May 2026 | Salveson Jon W | Director | Grant or award | +7,576 | — | 137,416 | Form 4 |
| 18 May 2026 | Semedo Anthony B. | Director | Grant or award | +7,576 | — | 46,960 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Artivion page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.